Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

PURPOSE: The Wee1 kinase inhibitor adavosertib abrogates cell cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase 2 dose (RPh2D). Here, we report results for once-daily adavosertib. PATIENTS AND METHODS...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Takebe, Naoko, Naqash, Abdul Rafeh, Coyne, Geraldine O’Sullivan, Kummar, Shivaani, Do, Khanh, Bruns, Ashley, Juwara, Lamin, Zlott, Jennifer, Rubinstein, Larry, Piekarz, Richard, Sharon, Elad, Streicher, Howard, Mittra, Arjun, Miller, Sarah B., Ji, Jiuping, Wilsker, Deborah, Kinders, Robert J., Parchment, Ralph E., Chen, Li, Chang, Ting-Chia, Das, Biswajit, Mugundu, Ganesh, Doroshow, James H., Chen, Alice P.
Format: Artigo
Langue:Inglês
Publié: 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8282703/
https://ncbi.nlm.nih.gov/pubmed/33863809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-21-0329
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires